catalyst · primary record
LP352 + Placebo
Phase readout · 2026-12-31 · Dravet Syndrome
| Company | Longboard Pharmaceuticals |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT06660394 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T10:37:32.780Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Longboard Pharmaceuticals:LP352 + Placebo:2026-12-31:P3 primary completion · NCT06660394
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.